ASBP Valuation

Aspire Biopharma Holdings Inc

Add to Watchlist

Advanced Chart

0.383

+0.006(1.594%)1D

ASBP Relative Valuation

ASBP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ASBP is overvalued; if below, it's undervalued.

Historical Valuation

Aspire Biopharma Holdings Inc (ASBP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.38 is considered Fairly compared with the five-year average of 0.00. The fair price of Aspire Biopharma Holdings Inc (ASBP) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.38

Fair

0.00

Trailing

Forward

0.00

EV/EBITDA

Aspire Biopharma Holdings Inc. (ASBP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.00

EV/EBIT

Aspire Biopharma Holdings Inc. (ASBP) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.

0.38

Aspire Biopharma Holdings Inc. (ASBP) has a current PS of 0.38. The 5-year average PS is 0.01. The thresholds are as follows: Strongly Undervalued below -0.12, Undervalued between -0.12 and -0.05, Fairly Valued between 0.07 and -0.05, Overvalued between 0.07 and 0.14, and Strongly Overvalued above 0.14. The current Forward PS of 0.38 falls within the Strongly Overvalued range.

0.00

P/OCF

Aspire Biopharma Holdings Inc. (ASBP) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

0.00

P/FCF

Aspire Biopharma Holdings Inc. (ASBP) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Aspire Biopharma Holdings Inc (ASBP) has a current Price-to-Book (P/B) ratio of -1.97. Compared to its 3-year average P/B ratio of -370.37 , the current P/B ratio is approximately -99.47% higher. Relative to its 5-year average P/B ratio of -370.37, the current P/B ratio is about -99.47% higher. Aspire Biopharma Holdings Inc (ASBP) has a Forward Free Cash Flow (FCF) yield of approximately -15.35%. Compared to its 3-year average FCF yield of -11.42%, the current FCF yield is approximately 34.46% lower. Relative to its 5-year average FCF yield of -11.42% , the current FCF yield is about 34.46% lower.

-1.97

P/B

Median3y

-370.37

Median5y

-370.37

-15.35

FCF Yield

Median3y

-11.42

Median5y

-11.42

Competitors Valuation Multiple

The average P/S ratio for ASBP's competitors is 2.86, providing a benchmark for relative valuation. Aspire Biopharma Holdings Inc Corp (ASBP) exhibits a P/S ratio of 0.38, which is -86.65% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ASBP.O

Aspire Biopharma Holdings Inc

Natural Alternatives International Inc

Curanex Pharmaceuticals Inc

0.68

19.20M

QLGN.O

Qualigen Therapeutics Inc

2.85

5.79M

Performance Decomposition

Market capitalization of ASBP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ASBP in the past 1 year is driven by Unknown.